PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30353564-1	2019	OBJECTIVES: The aim of this study was to evaluate a possible relationship between DRD2/ANKK1 (rs1800497) and SLC6A3/DAT1 (rs28363170) gene polymorphisms with the response to levodopa (L-DOPA)-therapy in patients with Parkinson"s disease (PD).	Levodopa	174-182	solute carrier family 6 member 3	Homo sapiens	109-115	
30353564-1	2019	OBJECTIVES: The aim of this study was to evaluate a possible relationship between DRD2/ANKK1 (rs1800497) and SLC6A3/DAT1 (rs28363170) gene polymorphisms with the response to levodopa (L-DOPA)-therapy in patients with Parkinson"s disease (PD).	Levodopa	174-182	solute carrier family 6 member 3	Homo sapiens	116-120	
30353564-1	2019	OBJECTIVES: The aim of this study was to evaluate a possible relationship between DRD2/ANKK1 (rs1800497) and SLC6A3/DAT1 (rs28363170) gene polymorphisms with the response to levodopa (L-DOPA)-therapy in patients with Parkinson"s disease (PD).	Levodopa	184-190	solute carrier family 6 member 3	Homo sapiens	109-115	
30353564-1	2019	OBJECTIVES: The aim of this study was to evaluate a possible relationship between DRD2/ANKK1 (rs1800497) and SLC6A3/DAT1 (rs28363170) gene polymorphisms with the response to levodopa (L-DOPA)-therapy in patients with Parkinson"s disease (PD).	Levodopa	184-190	solute carrier family 6 member 3	Homo sapiens	116-120	
30353564-7	2019	CONCLUSIONS: Clinical and demographic characteristics of Brazilian PD patients and differences in DRD2 and DAT1 genes may to determine individual variations in the therapeutic response to L-DOPA in the Brazilian PD patients.	Levodopa	188-194	solute carrier family 6 member 3	Homo sapiens	107-111